Inizio Evoke's Dom Elliston discusses what stood out at ASCO 2025 and what it means for the healthcare communications industry. Skip to main content Friday 27 June 2025 . BlueSky linkedin youtube ...

ASCO 2025 will feature the latest advancements in genitourinary cancer and melanoma treatment, focusing on the exciting developments in immunotherapy. Stay updated on the cutting-edge research and ...

Source: Getty Images Gastrointestinal cancer highlights from ASCO 2025 include results from BREAKWATER, MATTERHORN, ATOMIC, DESTINY-Gastric04, PANOVA-3, and other trials. Research presented at the ...

The YIA is a one-year grant totaling $50,000 that supports personnel and/or research expenses, and travel to attend the Conquer Cancer Grants & Awards Ceremony at the ASCO Annual Meeting. Applicants ...

The ideas and opinions expressed in the ASCO Reading Room do not necessarily reflect those of the American Society of Clinical Oncology. The mention of any product, service, ...

ASCO 2025: A Phase 1/2 First in Human Study of ADI-270, an Armored Allogeneic Anti-CD70 Chimeric Antigen Receptor γδ T Cell Therapy, in Relapsed or Refractory (R/R) Clear Cell Renal Cell Carcinoma ...

At the 2025 ASCO annual meeting, Dr. Hoffman-Censits reported an interim analysis of JAVELIN Bladder Medley assessing avelumab + sacituzumab govitecan versus avelumab monotherapy. Notably, this trial ...

Dale Shepard, MD, PhD, discusses the key themes emerging from the 2025 ASCO Annual Meeting, highlighting a prevailing sense of optimism driven by ongoing research. Read More. Dr Hamilton: ASCO 2025 ...